Paul Matteis
Stock Analyst at Stifel
(1.81)
# 2,931
Out of 4,667 analysts
101
Total ratings
31.67%
Success rate
-9.68%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Buy | $32 → $10 | $4.27 | +134.19% | 3 | Nov 13, 2024 | |
| NGNE Neurogene | Maintains: Buy | $44 → $60 | $15.33 | +291.39% | 2 | Nov 12, 2024 | |
| ALKS Alkermes | Upgrades: Buy | $25 → $36 | $27.91 | +28.99% | 8 | Nov 5, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $115 → $87 | $62.56 | +39.07% | 8 | Sep 17, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $41 → $66 | $29.99 | +120.07% | 3 | Aug 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $22.19 | +57.73% | 1 | Jul 2, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $50 → $53 | $35.40 | +49.72% | 5 | Jun 27, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $215 → $295 | $248.79 | +18.57% | 13 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $26 → $21 | $16.27 | +29.07% | 5 | May 9, 2024 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $29 | $13.65 | +112.45% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $20 | $4.91 | +307.33% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $123.29 | +16.80% | 8 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $156.00 | +83.97% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $15 | $3.64 | +312.65% | 3 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.12 | +226.80% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $373 | $451.23 | -17.34% | 17 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.61 | +359.77% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $9.79 | +165.58% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $4.40 | +445.45% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.64 | +678.45% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $8.96 | +257.14% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $3.05 | +686.89% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.37 | +1,039.24% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $10.95 | +137.44% | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $10.75 | +30.23% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $14.26 | +348.81% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $15.12 | +2,148.68% | 1 | Dec 21, 2016 |
Alto Neuroscience
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $4.27
Upside: +134.19%
Neurogene
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $15.33
Upside: +291.39%
Alkermes
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $27.91
Upside: +28.99%
BioMarin Pharmaceutical
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $62.56
Upside: +39.07%
Dyne Therapeutics
Aug 16, 2024
Maintains: Buy
Price Target: $41 → $66
Current: $29.99
Upside: +120.07%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $22.19
Upside: +57.73%
Ionis Pharmaceuticals
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $35.40
Upside: +49.72%
Alnylam Pharmaceuticals
Jun 27, 2024
Maintains: Buy
Price Target: $215 → $295
Current: $248.79
Upside: +18.57%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $16.27
Upside: +29.07%
Contineum Therapeutics
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $13.65
Upside: +112.45%
Dec 18, 2023
Maintains: Hold
Price Target: $22 → $20
Current: $4.91
Upside: +307.33%
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $123.29
Upside: +16.80%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $156.00
Upside: +83.97%
Dec 14, 2023
Upgrades: Buy
Price Target: $8 → $15
Current: $3.64
Upside: +312.65%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $6.12
Upside: +226.80%
Nov 22, 2023
Reiterates: Hold
Price Target: $373
Current: $451.23
Upside: -17.34%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $2.61
Upside: +359.77%
Oct 10, 2023
Initiates: Buy
Price Target: $26
Current: $9.79
Upside: +165.58%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $4.40
Upside: +445.45%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.64
Upside: +678.45%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $8.96
Upside: +257.14%
Feb 1, 2022
Initiates: Buy
Price Target: $24
Current: $3.05
Upside: +686.89%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $2.37
Upside: +1,039.24%
Jul 20, 2021
Initiates: Buy
Price Target: $26
Current: $10.95
Upside: +137.44%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $10.75
Upside: +30.23%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $14.26
Upside: +348.81%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $15.12
Upside: +2,148.68%